Evoke Pharma (EVOK) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to -$1.2 million.
- Evoke Pharma's Income towards Parent Company rose 1190.06% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.2 million, marking a year-over-year increase of 1497.85%. This contributed to the annual value of -$5.4 million for FY2024, which is 3131.43% up from last year.
- Per Evoke Pharma's latest filing, its Income towards Parent Company stood at -$1.2 million for Q3 2025, which was up 1190.06% from -$1.6 million recorded in Q2 2025.
- In the past 5 years, Evoke Pharma's Income towards Parent Company registered a high of -$1.2 million during Q3 2025, and its lowest value of -$2.7 million during Q1 2021.
- Its 5-year average for Income towards Parent Company is -$1.8 million, with a median of -$1.8 million in 2022.
- In the last 5 years, Evoke Pharma's Income towards Parent Company skyrocketed by 6712.34% in 2021 and then tumbled by 2397.05% in 2025.
- Evoke Pharma's Income towards Parent Company (Quarter) stood at -$1.7 million in 2021, then fell by 7.82% to -$1.8 million in 2022, then dropped by 10.21% to -$2.0 million in 2023, then skyrocketed by 39.98% to -$1.2 million in 2024, then increased by 3.06% to -$1.2 million in 2025.
- Its last three reported values are -$1.2 million in Q3 2025, -$1.6 million for Q2 2025, and -$1.3 million during Q1 2025.